Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Part 1: Number of Participants from 1 to <18 years of Age Who Experience a Dose-Limiting Toxicity (DLT)

  Measured over: Up to 42 days

• Part 1: Number of Participants from 1 to <18 years of Age Who Experience One or More Adverse Events (AEs)

  Measured over: Up to approximately 54 months

• Part 1: Number of Participants from 1 to <18 years of Age Who Discontinue Study Treatment Due to AEs

  Measured over: Up to approximately 54 months

• Part 1: Number of Participants from 1 to <18 years of Age Who Receive Dose Modification Due to AEs

  Measured over: Up to approximately 54 months

• Part 1 and Part 2: Objective Response (OR) for Participants with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  Measured over: Up to approximately 54 months

• Part 1 and Part 2: OR for Participants with Diffuse Large B-Cell Lymphoma (DLBCL)/Burkitt Lymphoma, Neuroblastoma, and Ewing Sarcoma

  Measured over: Up to approximately 54 months

Changes Tremor has spotted